Suppression of esophageal tumor growth and chemoresistance by directly targeting the PI3K/AKT pathway.
about
A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors.Significance of PI3K/AKT signaling pathway in metastasis of esophageal squamous cell carcinoma and its potential as a target for anti-metastasis therapy.Loss of miR-200b promotes invasion via activating the Kindlin-2/integrin β1/AKT pathway in esophageal squamous cell carcinoma: An E-cadherin-independent mechanismMelatonin enhances sensitivity to fluorouracil in oesophageal squamous cell carcinoma through inhibition of Erk and Akt pathwayDESC1, a novel tumor suppressor, sensitizes cells to apoptosis by downregulating the EGFR/AKT pathway in esophageal squamous cell carcinoma.Role of AMPK signaling in mediating the anticancer effects of silibinin in esophageal squamous cell carcinoma.Synergistic anticancer effect of combined crocetin and cisplatin on KYSE-150 cells via p53/p21 pathway.Alpha-Tocopherol prevents esophageal squamous cell carcinoma by modulating PPARγ-Akt signaling pathway at the early stage of carcinogenesis.RACKI induces chemotherapy resistance in esophageal carcinoma by upregulating the PI3K/AKT pathway and Bcl-2 expression.Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway.Knockdown of KLK11 reverses oxaliplatin resistance by inhibiting proliferation and activating apoptosis via suppressing the PI3K/AKT signal pathway in colorectal cancer cell.Bufalin induces apoptosis in human esophageal carcinoma ECA109 cells by inhibiting the activation of the mTOR/p70S6K pathway.Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours.A subset of esophageal squamous cell carcinoma patient-derived xenografts respond to cetuximab, which is predicted by high EGFR expression and amplification
P2860
Q33426930-B89A479E-1517-4654-9580-7A6ABE167B9CQ33888946-302A2A06-D21A-4F1B-B0FB-B6884E2D2162Q36557184-3D8FDEF0-2654-482F-AB91-3FC4377A6BCFQ37465949-297999AD-6B8D-4728-B588-4EBCF83B083AQ38795571-9615F2C9-F256-4A6D-B195-605D2A8A1F6DQ38819571-50BD927E-6C30-47E5-A301-683CC2BF5EAEQ43649979-7719C420-369F-4268-8128-CFF746A91483Q47097475-A4F5CE36-7065-45CD-B1DE-649347DD05C1Q49594035-C3DEAFA0-CBED-473F-9AC3-6A93D5CA70B0Q52660179-D2A15215-7A65-4170-95D6-D03B4CC213CBQ53705298-081FD2A1-EBDF-46CB-AB83-95A115A0EBEFQ54977984-4BF9C9C0-A435-4AA5-AF95-63BD02898C99Q55027485-0619F76C-1E3D-4A31-A9E4-A708547B9132Q58771181-AF7BE1E1-E721-484D-B801-2C46A003A144
P2860
Suppression of esophageal tumor growth and chemoresistance by directly targeting the PI3K/AKT pathway.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Suppression of esophageal tumo ...... argeting the PI3K/AKT pathway.
@ast
Suppression of esophageal tumo ...... argeting the PI3K/AKT pathway.
@en
Suppression of esophageal tumo ...... argeting the PI3K/AKT pathway.
@nl
type
label
Suppression of esophageal tumo ...... argeting the PI3K/AKT pathway.
@ast
Suppression of esophageal tumo ...... argeting the PI3K/AKT pathway.
@en
Suppression of esophageal tumo ...... argeting the PI3K/AKT pathway.
@nl
prefLabel
Suppression of esophageal tumo ...... argeting the PI3K/AKT pathway.
@ast
Suppression of esophageal tumo ...... argeting the PI3K/AKT pathway.
@en
Suppression of esophageal tumo ...... argeting the PI3K/AKT pathway.
@nl
P2093
P2860
P356
P1433
P1476
Suppression of esophageal tumo ...... targeting the PI3K/AKT pathway
@en
P2093
Annie L M Cheung
Li Yi Zhang
Sai Wah Tsao
Wen Wen Xu
Yan Ru Qin
P2860
P304
11576-11587
P356
10.18632/ONCOTARGET.2596
P407
P577
2014-11-01T00:00:00Z